ArticleCancer chemotherapy and pharmacology2021

Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies.

Shigehisa Kitano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.